Loading...
•
Dec 31, 2021
Fulcrum Therapeutics Q4 2021 Earnings Report
Provided a business update and reported financial results for the fourth quarter and full year of 2021.
Key Takeaways
Fulcrum Therapeutics reported collaboration revenue of $5.1 million for the fourth quarter of 2021, compared to $4.2 million for the fourth quarter of 2020. Research and development expenses were $18.9 million for the fourth quarter of 2021, as compared to $16.1 million for the fourth quarter of 2020. General and administrative expenses were $9.7 million for the fourth quarter of 2021, as compared to $5.9 million for the fourth quarter of 2020. Net loss was $23.5 million for the fourth quarter of 2021, as compared to a net loss of $17.7 million for the fourth quarter of 2020.
Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022
On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022
Engaged with U.S. and EU regulatory agencies, including the Food and Drug Administration (FDA), and gained alignment on key aspects of the design for a Phase 3 trial with losmapimod for FSHD.
Appointed Esther Rajavelu Fulcrum’s Chief Financial Officer in January 2022.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
Based on current plans, the company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2024.